

TB:HIV

an international prospective observational study



Newsletter: June 2015


Dear TB:HIV Study Investigators,

Thank you for your excellent work and continued contribution to the TB:HIV study. Below, please find an update on the TB:HIV study status.

FOLLOW-UP (FU) STATUS:

On 7 June 2015, we sent out a new batch of follow-up forms (177 24 months FU forms). We kindly ask you to return the follow-up forms to the coordinating centre as soon as possible - hopefully before the summer break. The deadline for returning these is **1 September 2015**. The 24 months FU form is the last follow-up form within the TB:HIV study and we kindly ask you to carefully verify all previously provided information on the form and correct where appropriate. The good quality data is essential for ensuring solid results.

If you have any questions regarding FU forms, please contact Bitten Aagaard (bitten.aagaard@regionh.dk) or the coordinating centre (tb-hiv.rigshospitalet@regionh.dk). Below, please find the final status of the December 2014 batch of follow-up forms:



LOSS TO FOLLOW-UP (LTFU):

It remains essential to the study that we collect as complete FU data as possible. LTFU may be overcome by contacting other clinics in the area, dispensaries, NGOs, accessing death registries etc. to find any information on patients that are currently LTFU. We strongly encourage all Investigators to prioritize this in order to minimize LTFU.

Upcoming deadlines and tasks:

By **1 September, 2015** you should have sent the following:

- Complete and return FU forms sent to your site in June 2015.
- Complete and return IRIS forms for patients who have developed IRIS.
- Complete and return CoDe forms for those patients who have died.

Upcoming conferences and scientific meetings:

- 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Vancouver 19-22 July 2015. Presentation: **Excess TB mortality in HIV patients in Eastern Europe: restructured approach to care needed.** Presented by Anna Schultze. Monday 20 July 2015, 2:30-4:00PM, Session Title: **HIV and TB: Gaps and Opportunities**, Session Room: Ballroom B. Abstract number: MOAB0203.
- 15th European AIDS Conference (EACS), Barcelona 21-24 October 2015: Tentative time for TB:HIV joint Investigator/Steering Committee meeting; 22 October 2015, from 12.30-13.30. Location: Class room 25. Lunch will be served. Final confirmation of time and location will follow.

Contacts for the Coordinating Centre (CHIP)

Case Report Forms: Bitten Aagaard:
bitten.aagaard@regionh.dk

Project Coordinator: Anne Marie Werlinrud Efsen:

anne.marie.werlinrud.efsen@regionh.dk (on maternity leave from December 2014)

Project Coordinator: Jakob Friis Larsen
jakob.friis.larsen@regionh.dk

Senior Coordinator: Daria Podlekareva:

MYCOBACTERIAL SAMPLES (Mtb samples):

We encourage all investigators to arrange storage of and send us mycobacterial samples cultured from the participating patients. Each sample is reimbursed by 30 Euro and shipment costs will be covered. Please contact us when you have samples ready for shipment.

SCIENTIFIC UPDATE:

Results on one year mortality in relation to presence of MDR-TB and the number of active drugs in the initial anti-TB regimen will be presented at IAS in Vancouver on Monday 20 July 2015:

Excess TB mortality in HIV patients in Eastern Europe: restructured approach to care needed. Presented by Anna Schultze for the TB:HIV study group in EuroCoord.

The following manuscript has been published and is available online:

Major differences in organisation and availability of healthcare and medicines for HIV/TB coinfecting patients across Europe. M Mansfeld, A Skrahina, L Shepherd, A Schultze, AM Panteleev, RF Miller, JM Miro, I Zeltina, S Tetrarov, H Furrer, O Kirk, A Grzeszczuk, N Bolokadze, A Matteelli, FA Post, JD Lundgren, A Mocroft, AM W Efsen, DN Podlekareva for the TB:HIV study group. HIV Medicine, January 2015. (IF: 3.454) [Epub ahead of print]

The **baseline manuscript** providing details on patient characteristics at the time of TB diagnosis is currently under review – we will get back to you as soon as we know more.

Again, we would like to emphasize that FU data will be extremely important to fulfil the study and further elucidate the course of treatment and outcome thereof for these patients.

Thank you for a continuous fruitful collaboration!



daria.podlekareva@regionh.dk

Study leader: Ole Kirk:

Ole.Kirk@regionh.dk

TB:HIV Study Group

Central /Northern Europe:

Belgium: Brussels

Denmark: Danish HIV Cohort

France: Aquitaine Cohort

Switzerland: Swiss HIV Cohort

United Kingdom: Cardiff, Leicester, London, Manchester, Sheffield

Eastern Europe:

Belarus: Gomel, Minsk, Svetlogorsk

Estonia: Ida-Viru county

Georgia: Tbilisi

Latvia: Riga

Lithuania: Vilnius

Poland: Bialystok, Warsaw, Wroclaw, Poznań, Krakow

Romania: Bucharest

Russia: Novgorod the Great, St. Petersburg, Samara

Ukraine: Crimea

Latin America:

Argentina: Buenos Aires

Chile: Santiago

México: México D.F.

Southern Europe:

Italy: Bari, Brescia, Genova, Monza, Palermo, Rome, Sanremo

Spain: Barcelona, Madrid, San Sebastián

TB:HIV Study Steering Committee

M. Bruyand, J. A. Caylá, D. Duiculescu (†), H.

Furrer, E. Girardi, M. H. Losso, J.D. Lundgren, R.

Miller, J.M. Miro, N. Obel, A. Panteleev (Co-Chair),

F. Post (Co- Chair), A. Skrahin, J. J. Toibaro

Update from EuroCoord

Please find the latest newsletter from EuroCoord at:

www.eurocoord.net



This project has received funding from the European Union's Seventh Framework Programme for research, technological development and demonstration under EuroCoord grant agreement n° 260694."